Navigation Links
ADVENTRX Announces Management Promotions
Date:2/4/2010

ts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to: ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; the possibility that patent claims covering ANX-530 will not issue or, if they do, that such claims, which likely will be limited to a specific intravenous emulsion formulation of vinorelbine, will not be sufficient to preclude development of other formulations of vinorelbine by competitors; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at '/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 IBM (NYSE: IBM ) and ... NCD Challenge , a competition among a number ... of students to find new ways to address the rise ... (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) Illnesses such ...
... bio-pharmaceutical companies lose the ability to communicate externally because ... internal Advocacy groups will become more important to a ... cost effectiveness of care by communicating concepts and arranging ... Since internal Advocacy groups are not known ...
Cached Medicine Technology:IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 2IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 3Pharmaceutical Advocacy Groups Focus on Value-of-Care Initiatives 2
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate ... Today, the business has introduced its new collection of ... promotion. , The new prom outfits are guaranteed to ... lover. They are specially designed for 2015. Anyone who ... should visit its website before Jan. 26, 2015, the ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... 2014 Over 700 toys, that’s what ... communities. That is 700 smiling little faces this holiday ... over $6000 in monetary donations was given to the ... the expenses they incur through the year. Some of ... A Child's Haven , Shrine's Children's Hospitals, Toys for ...
(Date:12/24/2014)... 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... litigation currently underway in Pennsylvania’s Philadelphia Court of Common ... 24, 2014, court documents indicate that 1,183 claims had ... who developed gynecomastia (male breast growth) and other complications ... indicates that this represents an increase of more than ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... The New AfterShingles.com Helps Educate Consumers About Shingles ... The Visiting Nurse Associations of America (VNAA), the ... on Aging (NCOA) today announced the re-launch of ... to help educate consumers about shingles and postherpetic ...
... awareness by exploring solutions to the most common health problem ... The causes and treatments of enlarged prostate will be ... 2009 at 6:30pm at the Doubletree Hotel in Rosemead. Also ... the prostate affects more than half of all men over ...
... AVAILABLE -SEATTLE, March 31 The sister ... mucous causing oxygen loss and brain damage while she ... Center in Edmonds, Wash., has filed suit against three ... Extendicare REIT. Norene McPherson,s 49-year-old sister, Lea Ann, died ...
... March 31 HealthWorldWeb , the premiere Health 2.0 ... appointment of Michael L. Millenson and J.D. Kleinke to the ... in the industry as supporters and advisors strengthens our belief ... 2.0 personalization is a very real need," said Daniel Kogan, ...
... separate cancer from benign mole, scientists say , , TUESDAY, ... melanoma skin cancer and a harmless mole can still ... But scientists say differences in levels of certain genetic ... Melanoma is the deadliest form of skin cancer. Standard ...
... Georgetown University Medical Center (GUMC) have been able to ... cord injury in preclinical studies. , Their research, published ... by Kimberly Byrnes, PhD, shows that inflammation following injury ... damage, and that an experimental agent is able to ...
Cached Medicine News:Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 2Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 3Health News:Elder Abuse Complaint Filed Against Extendicare 2Health News:Elder Abuse Complaint Filed Against Extendicare 3Health News:HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors 2Health News:Gene Screen Could Help Spot Melanoma 2Health News:By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies 2
... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: